Cyclodextrins as a Drug Delivery Carrier for Anti-Cancer Drugs
Abstract
Cyclodextrin “molecules are large with a number of hydrogen donors. Cyclodextrins are widely used as "molecular cages" in the pharmaceutical, agrochemical, food and cosmetic industries. In the pharmaceutical industry they are used as complexing agents to increase the aqueous solubility of poorly soluble drugs and to increase their bioavailability and stability. Chemotherapeutic treatment for cancer has limitations such as poor drug solubility, non-specificity, poor bioavailability and poor survival rate. The lack of efficient treatment has created the need to develop and implement novel technology based on combination strategy of cyclodextrin complexation and nanotechnology with a view to make the therapy more useful and acceptable. The review deals with cyclodextrin and its applications in anti-cancer drug delivery for cancer treatment.
Keywords:
Cyclodextrin, poor water solubility, drug delivery, cancer therapy, cyclodextrin, liposome
References
1. Szejtli J. Introduction and General Overview of Cyclodextrin Chemistry. Chemical Reviews. 1998;98(5):1743-54.
2. Vyas A, Saraf S, Saraf S. Cyclodextrin based novel drug delivery systems. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2008;62(1):23-42.
3. Gidwani B, Vyas A. A Comprehensive Review on Cyclodextrin-Based Carriers for Delivery of Chemotherapeutic Cytotoxic Anticancer Drugs. BioMed Research International. 2015;2015:15.
4. Vhora I, Patil S, Bhatt P, Gandhi R, Baradia D, Misra A. Receptor-targeted drug delivery: current perspective and challenges. Ther Deliv. 2014;5(9):1007-24.
5. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Advanced drug delivery reviews. 2007;59(7):645-66.
6. Roux M, Perly B, Djedaini-Pilard F. Self-assemblies of amphiphilic cyclodextrins. European biophysics journal: EBJ. 2007;36(8):861-7.
7. Hakkarainen B, Fujita K, Immel S, Kenne L, Sandstrom C. 1H NMR studies on the hydrogen-bonding network in mono-altro-beta-cyclodextrin and its complex with adamantane-1-carboxylic acid. Carbohydrate research. 2005;340(8):1539-45.
8. Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra A, et al. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. J Control Release. 2016;226:148-67.
9. Szente L, Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Advanced drug delivery reviews. 1999;36(1):17-28.
10. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: An updated review. AAPS PharmSciTech. 2005;6(2):E329-E57.
11. Tegge G. Szejtli, J.: Cyclodextrins and Their Inclusion Complexes (Cyclodextrine und ihre Einschlußkomplexe). Verlag der Ungarischen Akademie der Wissenschaften. Akadémiai Kiadó, Budapest 1982. 296 pages, with numerous tables and formulas, cloth DM 67,50. Starch - Stärke. 1982;34(11):395
12. Patil S, Bhatt P, Lalani R, Amrutiya J, Vhora I, Kolte A, et al. Low molecular weight chitosan–protamine conjugate for siRNA delivery with enhanced stability and transfection efficiency. RSC Advances. 2016;6(112):110951-63.
13. Del Valle EMM. Cyclodextrins and their uses: a review. Process Biochemistry. 2004;39(9):1033-46.
14. Vhora I, Lalani R, Bhatt P, Patil S, Patel H, Patel V, et al. Colloidally Stable Small Unilamellar Stearyl Amine Lipoplexes for Effective BMP-9 Gene Delivery to Stem Cells for Osteogenic Differentiation. AAPS PharmSciTech 2018: 3550-60.
15. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. Journal of pharmaceutical sciences. 1996;85(11):1142-69.
16. Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi R, et al. Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. Journal of Drug Delivery Science and Technology. 2018;45:334-45.
17. ZHANG J, LAN CQ, POST M, SIMARD B, DESLANDES Y, HSIEH TH. Design of Nanoparticles as Drug Carriers for Cancer Therapy. Cancer Genomics - Proteomics. 2006;3(3-4):147-57.
18. Patil S, Lalani R, Bhatt P, Vhora I, Patel V, Patel H, et al. Hydroxyethyl substituted linear polyethylenimine for safe and efficient delivery of siRNA therapeutics. RSC Advances. 2018;8(62):35461-73.
19. Kwon GS. Polymeric micelles for delivery of poorly water-soluble compounds. Critical reviews in therapeutic drug carrier systems. 2003;20(5):357-403.
20. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annual review of biomedical engineering. 2007;9:257-88.
21. Hemal Tandel PB, Keerti Jain, Aliasgar Shahiwala, Ambikanandan Misra. In-Vitro and In-Vivo Tools in Emerging Drug Delivery Scenario: Challenges and Updates. In: Misra ASaA, editor. In-Vitro and In-Vivo Tools in Drug Delivery Research for Optimum Clinical Outcomes: CRC Press; 2018.
22. Singh UV, Aithal KS, Udupa N. Physicochemical and Biological Studies of Inclusion Complex of Methotrexate with β-Cyclodextrin. Pharmacy and Pharmacology Communications. 1997;3(12):573-7.
23. Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. International Journal of Pharmaceutics. 2018;536(1):95-107.
24. Yavuz B, Bilensoy E, Vural İ, Şumnu M. Alternative oral exemestane formulation: Improved dissolution and permeation. International Journal of Pharmaceutics. 2010;398(1–2):137-45.
25. Peng M, Liu Y, Zhang H, Cui Y, Zhai G, Chen C. Photostability Study of Doxorubicin Aqueous Solution Enhanced by Inclusion Interaction between Doxorubicin and Hydroxypropyl-β-cyclodextrin. Chinese Journal of Chemistry. 2010;28(7):1291-5.
26. Lalani R, Misra A, Amrutiya J, Patel H, Bhatt P, Patel V. Challenges in Dermal Delivery of Therapeutic Antimicrobial Protein and Peptides. Curr Drug Metab. 2017;18(5):426-36.
27. Balaji A, Pandey V, Srinath M, Manavalan R. Synthesis and characterization studies of cisplatin/hydroxypropyl-β-cyclodextrin complex. Pharmacologyonline. 2009;1:1135-43.
28. Monnaert V, Betbeder D, Fenart L, Bricout H, Lenfant AM, Landry C, et al. Effects of γ- and Hydroxypropyl-γ-cyclodextrins on the Transport of Doxorubicin across an in Vitro Model of Blood-Brain Barrier. Journal of Pharmacology and Experimental Therapeutics. 2004;311(3):1115-20.
29. Jiang Y, Jiang X, Law K, Chen Y, Gu J, Zhang W, et al. Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-β-cyclodextrin and safety evaluation. International Journal of Pharmaceutics. 2011;415(1–2):252-8.
30. McCormack B, Gregoriadis G. Entrapment of cyclodextrin-drug complexes into liposomes: potential advantages in drug delivery. Journal of drug targeting. 1994;2(5):449-54.
31. Bhatt P. PD, Patel A., Patel A., Nagarsheth A. . Oral Controlled Release Systems: Current Strategies and Challenges. In: Misra A, Shahiwala A (eds) Novel Drug Delivery Technologies Springer, Singapore. 2019.
32. Bhatt P, Khatri N, Kumar M, Baradia D, Misra A. Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer. Drug Delivery. 2015;22(6):849-61.
33. Piel G, Piette M, Barillaro V, Castagne D, Evrard B, Delattre L. Betamethasone-in-cyclodextrin-in-liposome: The effect of cyclodextrins on encapsulation efficiency and release kinetics. International Journal of Pharmaceutics. 2006;312(1–2):75-82.
34. Patel P, Hanini A, Shah A, Patel D, Patel S, Bhatt P, et al. Surface Modification of Nanoparticles for Targeted Drug Delivery. In: Pathak YV, editor. Surface Modification of Nanoparticles for Targeted Drug Delivery. Cham: Springer International Publishing; 2019. p. 19-31.
35. Dhule SS, Penfornis P, Frazier T, Walker R, Feldman J, Tan G, et al. Curcumin-loaded gamma-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine: nanotechnology, biology and medicine. 2012;8(4):440-51.
36. Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved <em>in vitro< /em> efficacy on ovarian cancer cells. Cancer Research. 2016;76(14 Supplement):2065.
37. Patel K, Patel K. Challenges and Recent Progress of Nano Sized Drug Delivery Systems for Lung Cancer Therapy: A Review. HJHS [Internet]. 5Dec.2020 [cited 15Sep.2020];5(4):58-2. Available from:
http://www.hjhs.co.in/index.php/hjhs/article/view/85
38. Joshi D. Breast cancer treatment: survival facts and associated side effects. HJHS [Internet]. 26Jan.2019 [cited 15Sep.2020];4(1):34-0. Available from:
http://www.hjhs.co.in/index.php/hjhs/article/view/37
2. Vyas A, Saraf S, Saraf S. Cyclodextrin based novel drug delivery systems. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2008;62(1):23-42.
3. Gidwani B, Vyas A. A Comprehensive Review on Cyclodextrin-Based Carriers for Delivery of Chemotherapeutic Cytotoxic Anticancer Drugs. BioMed Research International. 2015;2015:15.
4. Vhora I, Patil S, Bhatt P, Gandhi R, Baradia D, Misra A. Receptor-targeted drug delivery: current perspective and challenges. Ther Deliv. 2014;5(9):1007-24.
5. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Advanced drug delivery reviews. 2007;59(7):645-66.
6. Roux M, Perly B, Djedaini-Pilard F. Self-assemblies of amphiphilic cyclodextrins. European biophysics journal: EBJ. 2007;36(8):861-7.
7. Hakkarainen B, Fujita K, Immel S, Kenne L, Sandstrom C. 1H NMR studies on the hydrogen-bonding network in mono-altro-beta-cyclodextrin and its complex with adamantane-1-carboxylic acid. Carbohydrate research. 2005;340(8):1539-45.
8. Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra A, et al. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. J Control Release. 2016;226:148-67.
9. Szente L, Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Advanced drug delivery reviews. 1999;36(1):17-28.
10. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: An updated review. AAPS PharmSciTech. 2005;6(2):E329-E57.
11. Tegge G. Szejtli, J.: Cyclodextrins and Their Inclusion Complexes (Cyclodextrine und ihre Einschlußkomplexe). Verlag der Ungarischen Akademie der Wissenschaften. Akadémiai Kiadó, Budapest 1982. 296 pages, with numerous tables and formulas, cloth DM 67,50. Starch - Stärke. 1982;34(11):395
12. Patil S, Bhatt P, Lalani R, Amrutiya J, Vhora I, Kolte A, et al. Low molecular weight chitosan–protamine conjugate for siRNA delivery with enhanced stability and transfection efficiency. RSC Advances. 2016;6(112):110951-63.
13. Del Valle EMM. Cyclodextrins and their uses: a review. Process Biochemistry. 2004;39(9):1033-46.
14. Vhora I, Lalani R, Bhatt P, Patil S, Patel H, Patel V, et al. Colloidally Stable Small Unilamellar Stearyl Amine Lipoplexes for Effective BMP-9 Gene Delivery to Stem Cells for Osteogenic Differentiation. AAPS PharmSciTech 2018: 3550-60.
15. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. Journal of pharmaceutical sciences. 1996;85(11):1142-69.
16. Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi R, et al. Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. Journal of Drug Delivery Science and Technology. 2018;45:334-45.
17. ZHANG J, LAN CQ, POST M, SIMARD B, DESLANDES Y, HSIEH TH. Design of Nanoparticles as Drug Carriers for Cancer Therapy. Cancer Genomics - Proteomics. 2006;3(3-4):147-57.
18. Patil S, Lalani R, Bhatt P, Vhora I, Patel V, Patel H, et al. Hydroxyethyl substituted linear polyethylenimine for safe and efficient delivery of siRNA therapeutics. RSC Advances. 2018;8(62):35461-73.
19. Kwon GS. Polymeric micelles for delivery of poorly water-soluble compounds. Critical reviews in therapeutic drug carrier systems. 2003;20(5):357-403.
20. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annual review of biomedical engineering. 2007;9:257-88.
21. Hemal Tandel PB, Keerti Jain, Aliasgar Shahiwala, Ambikanandan Misra. In-Vitro and In-Vivo Tools in Emerging Drug Delivery Scenario: Challenges and Updates. In: Misra ASaA, editor. In-Vitro and In-Vivo Tools in Drug Delivery Research for Optimum Clinical Outcomes: CRC Press; 2018.
22. Singh UV, Aithal KS, Udupa N. Physicochemical and Biological Studies of Inclusion Complex of Methotrexate with β-Cyclodextrin. Pharmacy and Pharmacology Communications. 1997;3(12):573-7.
23. Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. International Journal of Pharmaceutics. 2018;536(1):95-107.
24. Yavuz B, Bilensoy E, Vural İ, Şumnu M. Alternative oral exemestane formulation: Improved dissolution and permeation. International Journal of Pharmaceutics. 2010;398(1–2):137-45.
25. Peng M, Liu Y, Zhang H, Cui Y, Zhai G, Chen C. Photostability Study of Doxorubicin Aqueous Solution Enhanced by Inclusion Interaction between Doxorubicin and Hydroxypropyl-β-cyclodextrin. Chinese Journal of Chemistry. 2010;28(7):1291-5.
26. Lalani R, Misra A, Amrutiya J, Patel H, Bhatt P, Patel V. Challenges in Dermal Delivery of Therapeutic Antimicrobial Protein and Peptides. Curr Drug Metab. 2017;18(5):426-36.
27. Balaji A, Pandey V, Srinath M, Manavalan R. Synthesis and characterization studies of cisplatin/hydroxypropyl-β-cyclodextrin complex. Pharmacologyonline. 2009;1:1135-43.
28. Monnaert V, Betbeder D, Fenart L, Bricout H, Lenfant AM, Landry C, et al. Effects of γ- and Hydroxypropyl-γ-cyclodextrins on the Transport of Doxorubicin across an in Vitro Model of Blood-Brain Barrier. Journal of Pharmacology and Experimental Therapeutics. 2004;311(3):1115-20.
29. Jiang Y, Jiang X, Law K, Chen Y, Gu J, Zhang W, et al. Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-β-cyclodextrin and safety evaluation. International Journal of Pharmaceutics. 2011;415(1–2):252-8.
30. McCormack B, Gregoriadis G. Entrapment of cyclodextrin-drug complexes into liposomes: potential advantages in drug delivery. Journal of drug targeting. 1994;2(5):449-54.
31. Bhatt P. PD, Patel A., Patel A., Nagarsheth A. . Oral Controlled Release Systems: Current Strategies and Challenges. In: Misra A, Shahiwala A (eds) Novel Drug Delivery Technologies Springer, Singapore. 2019.
32. Bhatt P, Khatri N, Kumar M, Baradia D, Misra A. Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer. Drug Delivery. 2015;22(6):849-61.
33. Piel G, Piette M, Barillaro V, Castagne D, Evrard B, Delattre L. Betamethasone-in-cyclodextrin-in-liposome: The effect of cyclodextrins on encapsulation efficiency and release kinetics. International Journal of Pharmaceutics. 2006;312(1–2):75-82.
34. Patel P, Hanini A, Shah A, Patel D, Patel S, Bhatt P, et al. Surface Modification of Nanoparticles for Targeted Drug Delivery. In: Pathak YV, editor. Surface Modification of Nanoparticles for Targeted Drug Delivery. Cham: Springer International Publishing; 2019. p. 19-31.
35. Dhule SS, Penfornis P, Frazier T, Walker R, Feldman J, Tan G, et al. Curcumin-loaded gamma-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine: nanotechnology, biology and medicine. 2012;8(4):440-51.
36. Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved <em>in vitro< /em> efficacy on ovarian cancer cells. Cancer Research. 2016;76(14 Supplement):2065.
37. Patel K, Patel K. Challenges and Recent Progress of Nano Sized Drug Delivery Systems for Lung Cancer Therapy: A Review. HJHS [Internet]. 5Dec.2020 [cited 15Sep.2020];5(4):58-2. Available from:
http://www.hjhs.co.in/index.php/hjhs/article/view/85
38. Joshi D. Breast cancer treatment: survival facts and associated side effects. HJHS [Internet]. 26Jan.2019 [cited 15Sep.2020];4(1):34-0. Available from:
http://www.hjhs.co.in/index.php/hjhs/article/view/37
Statistics
1298 Views | 1414 Downloads
How to Cite
Trivedi, H., S. Chauhan, and S. Patel. “Cyclodextrins As a Drug Delivery Carrier for Anti-Cancer Drugs”. Himalayan Journal of Health Sciences, Vol. 5, no. 4, Dec. 2020, pp. 63-68, doi:10.22270/hjhs.v5i4.86.
Section
Review Article (s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Innovative Science & Technology affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJIST.
Download link for COPYRIGHT FORM
